The Role of Angiotensin-Converting Enzyme (ACE) Polymorphisms in the Risk of Development and Treatment of Diabetic Nephropathy

被引:2
|
作者
Krol-Kulikowska, Magdalena [1 ]
Abramenko, Nikita [2 ,3 ,4 ]
Jakubek, Milan [2 ,3 ,4 ]
Banasik, Miroslaw [5 ]
Kepinska, Marta [1 ]
机构
[1] Wroclaw Med Univ, Fac Pharm, Dept Pharmaceut Biochem, Borowska 211a, PL-50556 Wroclaw, Poland
[2] Charles Univ Prague, Fac Med 1, BIOCEV, Vestec 25250, Czech Republic
[3] Charles Univ Prague, Fac Med 1, Dept Paediat & Inherited Metab Disorders, Prague 12000, Czech Republic
[4] Gen Univ Hosp, Prague 12000, Czech Republic
[5] Wroclaw Med Univ, Fac Med, Dept & Clin Nephrol & Transplantat Med, Borowska 213, PL-50556 Wroclaw, Poland
关键词
diabetes nephropathy; kidney transplant; single nucleotide polymorphisms; ACE inhibitors; molecular docking; GENE POLYMORPHISMS; DOCKING; SYSTEM;
D O I
10.3390/jcm13040995
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Angiotensin-converting enzyme (ACE) is responsible for the production of angiotensin II, and increased production of angiotensin II is observed in diabetes. What is more, ACE polymorphisms may play a role in the development of diabetic nephropathy. The aim of this study was to assess the role of selected ACE polymorphisms (rs4343 and rs4646994) in the risk of development of diabetic nephropathy and in the likelihood of renal replacement therapy. Methods: ACE polymorphisms were analyzed in a group of 225 patients who were divided into three subgroups. The rs4343 polymorphism was determined using the PCR-RFLP, and the rs4646994 polymorphism was determined using the PCR. Molecular docking between domains of ACE and its ligands was performed by using AutoDock Vina. Results: The G/G genotype of rs4343 polymorphism is associated with increased odds of developing diabetic nephropathy. The G allele is also associated with a higher risk of this disease. Similar results were obtained in patients who had already had a kidney transplant as a result of diabetic nephropathy. Conclusions: The presence of G/G and G/A genotypes, and the G allele increases the likelihood of developing diabetic nephropathy. This may also be a risk factor for renal replacement therapy.
引用
收藏
页数:17
相关论文
共 50 条
  • [41] Tracheotomy of angioedema associated with treatment with angiotensin-converting enzyme inhibitors
    Schröder, T
    Sachse, F
    Rudack, C
    HNO, 2005, 53 (05) : 459 - 461
  • [42] Angiotensin-Converting Enzyme and Heart Failure
    Alvarez-Zaballos, Sara
    Martinez-Selles, Manuel
    FRONTIERS IN BIOSCIENCE-LANDMARK, 2023, 28 (07):
  • [43] Ontogeny of angiotensin-converting enzyme 2
    Song, Renfang
    Preston, Graeme
    Yosypiv, Ihor V.
    PEDIATRIC RESEARCH, 2012, 71 (01) : 13 - 19
  • [44] Nontraditional Roles of Angiotensin-Converting Enzyme
    Shen, Xiao Z.
    Ong, Frank S.
    Bernstein, Ellen A.
    Janjulia, Tea
    Blackwell, Wendell-Lamar B.
    Shah, Kandarp H.
    Taylor, Brian L.
    Gonzalez-Villalobos, Romer A.
    Fuchs, Sebastien
    Bernstein, Kenneth E.
    HYPERTENSION, 2012, 59 (04) : 763 - 768
  • [45] Insight into the binding of ACE-inhibitory peptides to angiotensin-converting enzyme: a molecular simulation
    Jiang, Zhenyan
    Zhang, Hansi
    Bian, Xuefeng
    Li, Jingfeng
    Li, Jing
    Zhang, Hui
    MOLECULAR SIMULATION, 2019, 45 (03) : 215 - 222
  • [46] Correlation between serum angiotensin-converting enzyme (ACE) levels and intervertebral disc degeneration
    Guo, Youfeng
    Guo, Kai
    Hu, Tao
    Wu, Desheng
    PEPTIDES, 2022, 157
  • [47] Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers for prevention and treatment of nephropathy associated with type 2 diabetes mellitus
    Hughes, DB
    Britton, ML
    PHARMACOTHERAPY, 2005, 25 (11): : 1602 - 1620
  • [48] Angiotensin-converting Enzyme Inhibition Improves the Effectiveness of Transcutaneous Carbon Dioxide Treatment
    Nemeth, Balazs
    Kiss, Istvan
    Jencsik, Timea
    Peter, Ivan
    Kreska, Zita
    Koszegi, Tamas
    Miseta, Attila
    Kustan, Peter
    Boncz, Imre
    Laczo, Andrea
    Ajtay, Zeno
    IN VIVO, 2017, 31 (03): : 425 - 428
  • [49] Interaction between polymorphisms in the renin–angiotensin–system and angiotensin-converting enzyme inhibitor or β-blocker use and the risk of myocardial infarction and stroke
    H Schelleman
    O H Klungel
    J C M Witteman
    M M B Breteler
    A Hofman
    C M van Duijn
    A de Boer
    B H Ch Stricker
    The Pharmacogenomics Journal, 2008, 8 : 400 - 407
  • [50] Considerations for Docking of Selective Angiotensin-Converting Enzyme Inhibitors
    Caballero, Julio
    MOLECULES, 2020, 25 (02):